N/A
Manufactured by GlaxoSmithKline LLC
13,088 FDA adverse event reports analyzed
Last updated: 2026-04-14
ATOVAQUONE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by GlaxoSmithKline LLC. The most commonly reported adverse reactions for ATOVAQUONE include OFF LABEL USE, PYREXIA, DIARRHOEA, DRUG INEFFECTIVE, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ATOVAQUONE.
Out of 7,479 classified reports for ATOVAQUONE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 13,088 FDA FAERS reports that mention ATOVAQUONE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, PYREXIA, DIARRHOEA, DRUG INEFFECTIVE, NAUSEA, PNEUMONIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list GlaxoSmithKline LLC in connection with ATOVAQUONE. Always verify the specific product and NDC with your pharmacist.